NORDIC | BIOTECH & HEALTHCARE Your insights into listed Danish & Nordic biotech & healthcare stocks.
In the past week, the Danish biotech and healthcare sector did not deliver any price changes. However, 2cureX continues to skyrocket with almost 5x return year-to-date. Furthermore, Cessatech announced positive study results with CT001 against acute pain, while also raising nearly MDKK 15. Evaxion, Fluoguide, and Saniona reported their Q1 results, while Genmab and Zealand Pharma received new price targets.
Latest news for the Danish biotech companies
Acarix AB has developed a technology to identify heart diseases. Moving forward, product sales are the main driver for the stock.
No news in the past week
Ascendis Pharma develops so-called prodrugs, which are medications that start in an inactive form and become active once inside the body. The main stock price driver going forward is the development and commercialization of its TransCon technology.
No news in the past week
Biosergen is developing BSG005 to treat serious and life-threatening fungal infections safely and with limited side effects, contrary to current drugs. The main price triggers are centered around product development and the ongoing clinical trials
No news in the past week
Cessatech develops pain treatments for children. The company is finalizing its phase 3 study for its lead candidate, and the main price driver will be the commercialization for this product.
Cessatech announced positive top-line results from its final CT001 Study 0202, where the primary endpoint was met. Furthermore, the company raised MDKK 14.8 at DKK 12.72 per share.
Curasight is focused on diagnosing (uTRACE) and treating cancer (uTREAT) through targeted radionuclide therapy. The benefit is treating cancer at the cellular level without harming healthy cells. The main driver of the stock moving forward is the financing of the portfolio as well as pipeline and partnership development. You can read our full investment case here (in Danish).
Following its rights issue, Curasight announced the completion of registration of shares, and the first day of trading is expected to be 6 June 2025, and the estimated date for conversion to ordinary shares is 10 June 2025.
DanCann Pharma focuses on discovering, developing, and producing medical cannabis for pain and neurological conditions. The stock price drivers are regulatory progress and sales development.
No news in the past week
Evaxion Biotech develops personalized immunotherapies and vaccines, with recent advancements in their cancer vaccine candidate EVX-01. Clinical trial outcomes and technological innovations currently drive the stock price.
Evaxion announced a business update and first quarter 2025 financial results, highlighting continued progression of the development of our lead asset EVX-01 with the ongoing phase 2 trial on track for two-year readout in the second half of 2025, and the first patient in the one-year trial extension being dosed in May.
ExpreS2ion provides protein production technologies for vaccine development and has its own pipeline. Key stock drivers include pipeline progression and licensing agreements.
No news in the past week
Fluoguide develops tumor-targeted products that make cancer visible on imaging solutions to improve cancer surgery outcomes, especially within brain and head & neck cancer surgery. The main stock driver is the clinical validation of their imaging technology and additional partnerships.
Fluoguide announced its first quarter results, including negative cash flows, while highlighting the first patients enrolled in CT-005 study
Genmab focuses on creating differentiated antibody therapeutics for the treatment of lymphatic leukemia and solid tumors. Genmab has developed Darzalex, with sales of nearly USD 12 billion in 2024. The stock performance is primarily driven by product sales and pipeline developments.
RBC lowered its price target from DKK 2,300 to 2,000.
Gubra offers preclinical contract research services and develops treatments for metabolic diseases. Key stock drivers are partnerships and progress in their internal drug pipeline.
No news in the past week
Initiator Pharma develops treatments for erectile dysfunction and neuropathic pain. The main stock catalyst is the outcome of clinical trials.
Initiator Pharma updated the timeline of its rights issue of MSEK 56, which is 86% secured. The subscription period runs from the 12-26 June 2025.
IO Biotech is developing immune-modulating therapies for cancer, with a focus on conditions like melanoma. Stock performance is driven by clinical trial advancements.
No news in the past week
Pila Pharma is working on TRPV1 antagonists aimed at treating type 2 diabetes. Early clinical data and funding developments are key stock drivers.
No news in the past week
Saniona focuses on ion channel-targeted therapies, including rare eating disorders. The main stock driver is the progression of their clinical pipeline and the approval of the weight loss drug Tesofensine in Mexico.
Saniona announced its interim report for the first quarter of 2025, emphasizing restart of its three internal development programs.
Scandion Oncology is developing treatments to overcome chemotherapy resistance in cancer patients. The company has recently faced significant financial challenges, thus, financial stability is the main driver for the stock price.
No news in the past week
SynAct Pharma develops drugs targeting inflammatory diseases through melanocortin pathways. Clinical milestones significantly influence stock performance
Saniona announced its interim report for the first quarter of 2025, emphasizing the potential of AP1189 against chronic diseases.
ViroGates provides prognostic products for acute care settings to improve patient triage. Stock drivers include hospital adoption rates and revenue growth.
No news in the past week
Y-mAbs Therapeutics develops antibody-based therapies for pediatric cancers. Stock performance is driven by regulatory approvals and commercialization efforts.
Y-mAbs Therapeutics presented GD2-SADA PRIT trial in progress poster at the Advances in Neuroblastoma Research Meeting of 2025
Zealand Pharma specializes in peptide-based treatments for metabolic and gastrointestinal diseases. The stock has seen increased awareness following the obesity hype, and advancements in its late-stage pipeline and partnerships are key stock price influencers.
Danske Bank set a new price target of DKK 800. In addition, Zealand Pharma submitted marketing authorization application to the European Medicines Agency for glepaglutide in short bowel syndrome.
2cureX offers the IndiTreat platform for individualized cancer treatment testing. The main stock driver is the adoption of their technology by hospitals and subsequent sales growth.
No news in the past week
The latest share price developments for the Danish biotech stocks
On average, the Danish biotech and healthcare stocks did not deliver any changes in the past week. Four stocks, however, delivered a double-digit return. Most notably, 2cureX continues to rise without any news. The stock is now up almost 5x year-to-date. Cessatech announced positive top-line results from its final CT001 Study 0202, where the primary endpoint was met. Furthermore, the company raised MDKK 14.8 at DKK 12.72 per share. Evaxion, Fluoguide, and Saniona announced its first quarter results, highlighting pipeline progress. Saniona, in particular, has restarted several internal development programs following a large capital raise of MSEK 115. Finally, Genmab and Zealand Pharma received new price targets at DKK 2,300 and DKK 800, respectively.
Overview of share price development in the past week, year-to-date, and the last twelve months
DanCann Pharma does not appear on the list due to data issues.
Inhalation Sciences AB is raising capital; you can participate!
Inhalation Sciences AB is a research company. Today, the main focus is on the production and development of laboratory instruments. The instruments are used to measure particles in the inhaled air and to measure how the composition of the air affects the lungs. The company will raise SEK 15.2 million before issue costs, and the last day of subscription is June 3, 2025.
Furthermore, Aptahem AB has completed its rights issue, and we are now waiting for the final outcome to be announced.
